Chimeric antigen receptors targeting BCMA and methods of use thereof
US11535677B2 · kind B2 · utility
1Cited by
2References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2017 |
| Grant date | Dec 27, 2022 |
| Priority date | — |
| Expiry date | May 9, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.